189 related articles for article (PubMed ID: 6421112)
1. DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism.
Narabayashi H; Kondo T; Nagatsu T; Hayashi A; Suzuki T
Adv Neurol; 1984; 40():497-502. PubMed ID: 6421112
[No Abstract] [Full Text] [Related]
2. [L-threo-DOPS therapy and parkinsonism].
Narabayashi H
No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
[No Abstract] [Full Text] [Related]
3. Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Narabayashi H; Kondo T; Yokochi F; Nagatsu T
Adv Neurol; 1987; 45():593-602. PubMed ID: 3103397
[No Abstract] [Full Text] [Related]
4. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Maruyama W; Naoi M; Narabayashi H
J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
[TBL] [Abstract][Full Text] [Related]
5. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
Kondo T
Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
[No Abstract] [Full Text] [Related]
6. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z
Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
[TBL] [Abstract][Full Text] [Related]
7. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
Ogawa N; Yamamoto M; Takayama H
J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
[TBL] [Abstract][Full Text] [Related]
8. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Birkmayer W; Birkmayer G; Lechner H; Riederer P
J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
[TBL] [Abstract][Full Text] [Related]
9. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
[TBL] [Abstract][Full Text] [Related]
10. [The effect of L-threo-DOPS on P-300 in parkinsonism].
Yokota J; Itoh T; Imai H; Narabayashi H
Rinsho Shinkeigaku; 1990 May; 30(5):499-504. PubMed ID: 2119267
[TBL] [Abstract][Full Text] [Related]
11. Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Reches A
Clin Neuropharmacol; 1985; 8(3):249-59. PubMed ID: 3930069
[No Abstract] [Full Text] [Related]
12. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
Narabayashi H
No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
[No Abstract] [Full Text] [Related]
13. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
Yamamoto M; Ogawa N; Ujike H
J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
[TBL] [Abstract][Full Text] [Related]
14. Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Saito S; Shioda K; Nishijima K
J Clin Psychopharmacol; 2012 Jun; 32(3):428-9. PubMed ID: 22561478
[No Abstract] [Full Text] [Related]
15. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
Namba S; Ishimitsu H; Nakasone S
No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908
[No Abstract] [Full Text] [Related]
16. [Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism].
Nagatsu T
Nihon Rinsho; 1988 Sep; 46(9):2086-97. PubMed ID: 2907356
[No Abstract] [Full Text] [Related]
17. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine.
Bartholini J; Constantinidis J; Puig M; Tissot R; Pletscher A
J Pharmacol Exp Ther; 1975 May; 193(2):523-32. PubMed ID: 1142103
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease].
Narabayashi H; Yokochi F; Ogawa T; Igakura T
No To Shinkei; 1991 Mar; 43(3):263-8. PubMed ID: 1907469
[TBL] [Abstract][Full Text] [Related]
19. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Tohgi H; Abe T; Takahashi S; Takahashi J; Ueno M; Nozaki Y
Neurosci Lett; 1990 Aug; 116(1-2):194-7. PubMed ID: 2259448
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of orthostatic hypotension by noradrenaline supplement].
Hayashi A
No To Shinkei; 1985 Jul; 37(7):665-9. PubMed ID: 3933534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
